Abiopharma

ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004

Ardelyx Reports Preliminary 2025 Revenue and Provides 2026 Strategic Outlook

GeneDx and Komodo Health Partner to Build the World’s Most Complete Longitudinal Rare Disease Dataset

Veeva and BioMarin Form Long-Term Strategic Partnership

NAMSA Announces Strategic Acquisition of Select Assets of the Early Development Medical Device Testing Business of Labcorp

Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T

Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates

VTYX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Ventyx Biosciences, Inc. is Fair to Shareholders

New Form SCHEDULE 13G/A - SCYNEXIS INC Filed: 2026-01-08 AccNo: 0001623632-26-000036 Size: 46 KB

New Form SCHEDULE 13G/A - IDEAYA Biosciences, Inc. Filed: 2026-01-08 AccNo: 0001623632-26-000034 Size: 47 KB

(85% Positive) Voyager Therapeutics, Inc. (VYGR) Files Form 8-K

(99% Neutral) CORMEDIX INC. (CRMD) Reports Q1 2026 Financial Results

New Form SCHEDULE 13G/A - Arcturus Therapeutics Holdings Inc. Filed: 2026-01-08 AccNo: 0001623632-26-000033 Size: 46 KB

(99% Neutral) Coya Therapeutics, Inc. (COYA) Announces Clinical Development Update

ProQR Therapeutics (PRQR) Files Form 6-K